Skip to content

Edgewise Therapeutics

US · EWTX #2209 by market cap Listed 2021
39.57 -0.45 -1.12%
Live - 5344 symbols - heartbeat 108s ago · 2026-10-08 08:06
Pre-market 39.99 +1.06%
After-hours 40.26 +1.74%
Market cap
4.30B
P/B
9.59
EPS
-1.63
Reader sentiment Are you bullish or bearish on EWTX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $59
    Market Newswire · 2026/9/23
  • Rating change
    Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
    Market Newswire · 2026/9/23
  • Rating change
    Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $55
    Market Newswire · 2026/7/20
  • Rating change
    Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51
    Market Newswire · 2026/7/10
  • H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $57
    Market Newswire · 2026/9/23
  • Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $53
    Market Newswire · 2026/9/23
  • Rating change
    Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $52
    Market Newswire · 2026/6/4
  • Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Edgewise Therapeutics (EWTX)
    TipRanks · 2026/9/25
  • Rating change
    J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $60
    Market Newswire · 2026/8/20
  • H.C. Wainwright Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $57
    Market Newswire · 2026/9/21
  • Rating change
    H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/8/7
  • Rating change
    Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/8/7
  • Rating change
    J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $53
    Market Newswire · 2026/6/6
  • Rating change
    J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/8/20
  • Rating change
    J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/6/2
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX)
    TipRanks · 2026/9/23
  • Rating change
    A Quick Look at Today's Ratings for Edgewise Therapeutics(EWTX.US), With a Forecast Between $41 to $59
    Market Newswire · 2026/6/18
  • Rating change
    H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $45
    Market Newswire · 2026/6/3
  • Rating change
    Guggenheim Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51
    Market Newswire · 2026/7/6
  • Rating change
    Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $52
    Market Newswire · 2026/6/2

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:06:22 · For reference only, not investment advice and not tailored to your situation.